Senesonics is developing a minimally invasive continuous glucose monitoring system, which is designed to improve the management of type II diabetes. The company markets a device for making physiological measurements during exercise. In December 2015, Senseonics completed a reverse merger with ASN Technologies and went public on the New York Stock Exchange in March 2016.